Dyne Therapeutics, Inc.
US ˙ NasdaqGS ˙ US26818M1080

SecurityDYN / Dyne Therapeutics, Inc.
InstitutionStandard Life Aberdeen plc
Latest Disclosed Ownership1,430,384 shares
Latest Disclosed Value $ 25,932,862
Standard Life Aberdeen plc reports 29.08% increase in ownership of DYN / Dyne Therapeutics, Inc.

On April 29, 2026 - Standard Life Aberdeen plc filed a 13F-HR form disclosing ownership of 1,430,384 shares of Dyne Therapeutics, Inc. (US:DYN) valued at $25,932,862 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 1,108,145 shares of Dyne Therapeutics, Inc.. This represents a change in shares of 29.08% during the quarter. The current value of the position is $24,373,743 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-03-31 13F DYNE THERAPEUTICS COM 26818M108 1,430,384 322,239 29.08 25,933 19.64 0.0227
2026-01-16 2025-12-31 13F DYNE THERAPEUTICS COM 26818M108 1,108,145 551,412 99.04 21,675 207.80 0.0336
2025-11-07 2025-09-30 13F DYNE THERAPEUTICS COM 26818M108 556,733 72,770 15.04 7,043 52.85 0.0111
2025-07-24 2025-06-30 13F DYNE THERAPEUTICS COM 26818M108 483,963 169,377 53.84 4,607 40.03 0.0078
2025-05-13 2025-03-31 13F DYNE THERAPEUTICS COM 26818M108 314,586 288,783 1,119.18 3,291 442.01 0.0064
2025-01-24 2024-12-31 13F DYNE THERAPEUTICS COM 26818M108 25,803 25,803 608 0.0011
2024-10-25 2024-09-30 13F DYNE THERAPEUTICS COM 26818M108 0 -17,869 -100.00 0 -100.00
2024-08-09 2024-06-30 13F DYNE THERAPEUTICS COM 26818M108 17,869 17,869 631 0.0012
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.